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Erythropoietin (EPO) in hemodlalysis (HD) patients Effects on dialysis
parameters and nutritional status. P. Stroumza, N. Cano, P. Lacombe,
Clinique Residence du Parc, 13010 Marseille, France. The effects of
erythropoietin on nutritional status and dialysis parameters have been
poorly documented (Nephrologie Ii 5—10, 1990). in a retrospective
study of 92 HD patients (56 women and 36 men, aged 57 17 years,
mean SD), the incidence of EPO on hemoglobinemia, dry body
weight, serum albumin, transthyretin (prealbumin, TTR), protein cata-
bolic rate (pcr, g/kg/day), dialysis index (KT/V = In [BUN before
HD/BUN after HD)) and nerve conduction velocity (NCV) was evalu-
ated. EPO (50 U/kg, i.v., 2 times weekly) was administered during a 6.5
2.5 month period (1 to 9 months). Each parameter was measured
before and after EPO treatment and variations () were studied by
Student's paired t-test. Correlation coefficients between the different
variables were calculated. EPO treatment induced an increase in
hemoglobinemia ( Hg = 1.1 1.1 g/100 ml, P < 0.001) and pcr ( per
= 0.087 0.2 g/kg/day, P < 0.001) without any significant change in
other variables. z per and TTR were correlated (r = 0.291, P < 0.02).
Thus, EPO administration during a 6.5 2.5 month period was in this
series associated with an increase in per which reflected an elevation in
protein intake. A significant relationship between per and TTR varia-
tions was also demonstrated. This suggests that a longer period of EPO
treatment should be followed by an increase in visceral protein synthe-
sis, After such duration of EPO administration, no change in KT/V was
observed.
Clinical and virological evolution of cytomegalovirus infections treated
by Gancyclovir in renal transplantation. C. Pouteil-Noble, S.
Bosshard*, C. Rouvier, M. Aymard, J.L. Touraine, Transplantation
Unit, INSERM U 80-Hôpital E. Herriot, Virology Unit, Rockefeller-
Faculty, Lyon, France. Between 1/Jan./1989 and l/June/1990 46 renal
transplant patients, including 14 pancreatic and renal transplant pa-
tients, received Gancyclovir at a mean dose of 6.2 4mg/kg/day for 10
to 14 days for cytomegalovirus (CMV) infection diagnosed by serocon-
version and/or positive blood or urine viral isolation. Forty-one patients
received I treatment, 4 received 2 and I received 3, for a total of 52
treatments. The indications of treatment were: (1) symptomatic CMV
Infections in 90% of the cases (47/52) with fever in 79%; leukopenia in
75%; liver abnomalies in 42%; pneumopathy in 6%; and associated
renal dysfunction in 46% of the cases. (2) Asymptomatic CMV infection
associated with monoclonal (OKT3-Ortho) or polyclonal (ATG-Mer-
leux) globulin therapy for steroid-resistant rejection episodes was found
in 10% of cases (5/52). Primary infection (P1) was observed in 20/46
patients (43%) and 2 patients had active infection at the time of
transplantation. Antiviral therapy was started 49 6 days after trans-
plantation (median: 38 days) and 14 3.8 days after virological
diagnosis of the CMV infection. The clinical response was favorable
with a rapid disappearance of the fever in 83% of the cases. Leukopenia
was improved in 41% of the cases (16/39), worsened in 15%, and
remained stable in 44% during treatment. Renal function was improved
in 40% of the cases (2 1/52), worsened in 6%, and was unchanged in 54%
of the cases. No death due to CMV infection was observed, while 50%
mortality in P1 was found in transplanted patients from 1980 to 1984.
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The virological response was assessed by serologies and blood and
urine viral cultures weekly for at least 1 month. Negativation was
obtained in 5 1/52 treatments during therapy within Ito 7 days. Only one
case of resistance occurred. However, repositivation of the excretion
was noted in 54% of the cases (22/41) at a mean of 29 8 days after the
end of treatment, Among these recurrences 17 were in P1(77%) and of
23 treatments given in P1 patients, 74% had a recurrent excretion versus
only 28% (5/18) in reinfections. After Gancyclovir therapy the incidence
of chronic viruria (>1 month) in P1 was not significantly different from
an untreated P1 group: 47% (8/17) vs. 57% (20/35). Seroconversion was
not influenced by early administration of Gancyclovir. In conclusion,
the clinical response to Gancyclovir was favorable. The virological
response was almost constant during therapy but recurrences were
observed in more than 3/4 of primary infections after therapy was
discontinued. The incidence of persistent viruria, associated with a
poor renal prognosis, was not modified by the antiviral therapy.
Hepatitis C virus infection in renal transplantation. C. Pouteil-Noble,
J.C. Tardy', P. Chossegros, C. Trépo, M. Aymard, and J.L. Touraine,
Transplantation Unit-INSERM U80 Hôpital E. Herriot and Virology
Unit, Rockefeller Faculty, Lyon, France. The incidence of hepatitis C
virus (HCV) infection, its morbidity and the viral transmission by the
kidney were investigated in 189 renal recipients transplanted in 1983
and 1984. On the day of transplantation, sera of the recipient and of his
respective donor were tested for antiHCV antibodies (ORTHO). The
overall incidence, 24% (46/189), was much higher than in the normal
population and depended greatly on the geographic origin of the
recipient, ranging from 13.5% to 87.5% in Mediterranean recipients.
The incidence of HBV infection in the same population was 13.75%
(26/189) and 15% of the HCV infected patients were also HBV infected.
AntiHBc antibodies were found in 73% (27/37) of the HCV infected
patients at the time of transplantation. A previous history of HBV
infection was found in 35% of the patients and 3 patients had overt
hepatitis without HBV markers. All the patients had been previously
transfused, with a mean of 7.4 1.8 (1—60) transfusions. Liver
abnormalities were present in 11 patients (33%) on the day of trans-
plantation and this incidence increased to 65% (17/26) at 6 months and
to 71% at 1 year. At the end of the follow-up, ranging from 8 days to 84
months, 50% of the patients had anomalies of liver function. Liver
biopsy was available in 7 patients and 4 of them showed cirrhosis,
Leukopenia was extremely frequent: 13/33 (39%) in HCV infected
patients and might reflect the increased susceptibility of azathioprine
toxicity in these recipients. Graft and patient survival were not signif-
icantly different in patients with liver dysfunction as compared to
patients with normal laboratory parameters. However, one patient died
from cirrhosis due to both HBV and HCV infections. The incidence of
antiflCV antibodies in the corresponding 52 kidney donors was 4%, and
one recipient transplanted with a positive donor developed antiHCV
antibodies later but also received transfusions before the seroconver-
sion. This study shows (1) a high prevalence of HCV infected renal
patients at the time of transplantation; (2) a high incidence of liver
abnormalities in the first 6 months post-transplantation suggesting a role
of immunosuppressive therapy on the morbidity and the mortality of
HCV infection; (3) possible HCV transmission by the kidney that
should lead to the same donor selection as for blood transfusion.
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Calcified aortic stenosis: A non-exceptional cause of mortality in
hemodialyzed patients. A. Moynot, M. Bellorini, f.M. Berthelot, D.
Chiappini-Judith, M. Ferragu-Haguet, J.P. Masselot, R. Sari, N.
Simon, A. U.R.A. Bessin, Paris; Service de Cardiologie CHR Pontoise;
and A.U.R.A. Peupliers, Paris, France. We report 6 cases of calcified
aortic stenosis (CAS) with rapid evolution, appearing 3 to 120 months
(mean: 62) after the beginning of hemodialysis (HD). In comparison
with the CAS of non-HD patients, these cases of CAS are characterized
by the precocity of their appearance (age 47 to 70; mean 59.8), the
drastic rapidity of their evolution (10 to 18 months; mean: 14.8) and the
severity of their prognosis. Five of the six patients died: two of them six
months after refusal of operation, three others during exploration or
surgery. The last patient is waiting for surgery. The mean of plasmatic
phosphocalcic products before dialysis and during the evolution period
was high in the six patients: 2 patients > S mmoli'liter, 2 patients > 4.5
and 2 patients > 4. The severity of this not rare complication (S cases
in 4 years in a 200-patient center) would justify its routine search by
Doppler echocardiography annually, repeated every 3 months in case of
appearance of CAS, in order to propose early surgery. Based on the
dramatic evolution in our patients, we think that aortic valve replace-
ment must be proposed before the appearance of clinical symptoms.
Bilateral papillar edema. An unusual complication of vascular access
for hemodialysis. M. Ferragu-Haguet, P. Bourquelot, J.M. Bert helot,
B. Bourgeon, A. Moynot, C. Jacquot, A.U.R.A.-Bessin, Saint-Joseph
Hospital, and Broussais Hospital, Paris, France. Thrombosis or ste-
nosis of the venous side of an upper limb arterio-venous fistula (AVF)
is seldom responsible for serious side effects. In a 55-year-old woman,
hemodialyzed for 2 years, failure of previous vascular accesses led to
left brachial-auxillary graft in 1982. In 1984 temporary right and left
subclavian catheterism was performed for gram negative septicemia.
One year later angiography disclosed innominate vein thrombosis with
back flow via the left internal jugular vein (LIJV). A few months later
the patient complained of partial loss of sight, and fundoscopic exam-
ination revealed bilateral papillar edema suggesting hypertensive reti-
nopathy, in spite of moderate hypertension (160-100 mm Hg). CT
scanner was within normal limits. Fundoscopic abnormalities resolved
with antihypertensive therapy. In 1989, stenosis of the graft-auxiliary
vein anastomosis led to a by-pass between the graft and the LIJV. (A
right vascular access was impossible because of stenosis of the subcla-
vian vein). Two months later the patient complained of blurred vision.
Fundoscopic examination and retinal angiography showed bilateral
papiilar edema without hypertensive changes. Transposition of the
LIJV to the right was followed by rapid visual improvement. This
observation points both to the risk of severe retinal changes when a high
flow brachial AVF is derived via the LIJV because of innominate vein
occlusion, and to the importance of regular fundoscopic examination in
such a situation.
Dialysis membrane permeability to HBs Ag. A. Moynot, P. Dubreuil,
F, Daniel, J. Pillot, A.U.R.A., Paris, Antoine-Béclère Hospital, CIa-
mart, France. The hypothesis of convective transport of high molecular
weight (MW) endotoxins and/or viral particles through dialysis mem-
branes (DM) was tested. We measured HB5Ag (MW = 2 x 106) by
Elisa, HBeAg and anti-HBe by R.I.A., and IgG, 1gM and IgA by laser
nephelemetry in serum samples and in 100 x concentrated ultrafiltrate
(UF x 100) of 16 chronic HBsAg (+) hemodialyzed patients (pts). We
also measured a2 = microglobulin and apolipoproteins by laser nephe-
lemetry in each UF x 100. Ultrafiltration sessions were done 4 times
with each of the following DM: polyacylonitrile (PAN), polysulfone
(PSF), cuprophan (CUP), and cellulose acetate (CA). Hbs Ag was
found in 9/16 UF x 100 (PAN = 2, PSF = 3, CUP = 2, CA = 2). HBeAg(3 pts) was never found; anti-HBe (13 pts) was found twice in UF x 100
(PAN = I, PSF = I). Neither Ig nor a2 = microglobulin and apolipo-
proteins could be detected by the method used. HBsAg UF x 100 levels
(0.3—9 ng/mi) were correlated neither to the type of membrane nor to
HBsAg serum levels (3—90 y/ml). However, HB5Ag molecule integrity
remains to be tested by Western blot. We conclude that convection
probably allows the transfer of some large molecules (HbsAg in this
study) whatever the sieving coefficients of the membranes, due to
ultrafiltration, and perhaps by back filtration.
Do three daily exchanges provide adequate CAPD? P. Trolliet, B.
Fran cois, R. Cahen, B. Glathoud, M. Estrade, M. Trumpf, Nephrology
Division, C.H.U. Lyon-Sud, France. A CAPD regimen with 3 x 2.5 or
3 liters a day has been our policy since March 1988 and has been used
in 17 patients (8M, 9F), aged 5&-81 (mean: 70), followed for 3—21 (mean:
12) month periods. Etiology of ESRD was diabetic glomerulosclerosis
(3), atheromatous renal disease (3), chronic glomerulonephritis (2),
chronic pyelonephritis (1), and unknown (7); diabetes was present in 6
cases. All patients were initially tested with 3 liter then exchanges,
depending on tolerance, changed to 2.5 liter (N = 14) or maintained on
3 liter (N = 3) bags of 1.36% glucose solution and, when required,
3.86%. A daily hypertonic exchange was necessary in 9 cases. Fol-
low-up parameters were as follows (mean + SD):
Follow-up (months)
Patients, N
1
17
3
16
6
15
9
10
12
7
15
6
18
3
Serum creatinine 622 656 673 684 706 722 659
pmolIliter ±152 ±143 ±149 ±158 ±118 ±70 ±15
Resid. Cr clearance 3.9 3.6 3.2 2.8 3.2 2.2 2.6
mI/mm ±1.8 ±2.4 ±2.1 ±2 ±2.4 ±1 ±1
Periton. Cr 4.7 4.9 4.3 4.5 4.6 4.4 4.9
clearance ±1 ±1.2 ±0.8 ±1 ±1.1 ±0.5 ±0.5
mi/mm
Serum total protein 65 63 65 67 65 65 64
glliter ±7 ±7 ±6 ±6 ±5 ±5 ±2
Hemoglobin 87 97 103 103 104 106 104
g/liter ±10 ±11 ±18 ±18 ±13 ±13 ±13
Fourteen patients are still being treated; I has died and 2 have been
switched to HD. Peritonitis has occurred at the rate of 0.42 episode per
patient-year. No hernias, respiratory complications or reduction of
ultrafiltration have been encountered in this series. Three exchanges a
day, performed before or after meals, save time and resources, favor
resumption of working schedules and ease conditions of life in depen-
dent elderly patients. A progressive increase in serum creatinine with
concurrent loss of residual renal function might be a long-term limiting
factor.
Role of thromboxane A2 in the responses to norepinephrine of isolated
kidneys of Lyon genetically hypertensive rats. K.L. Liu, D. Benzoni, A.
Hadj AIssa, M. Vincent, J. Sassard, URA CNRS 606, Faculty of
Pharmacy and Department of Renal Function Studies, E. Herriot
Hospital, Lyon, France. In response to norepinephrine (NE) adminis-
tration, isolated perfused kidneys of Lyon genetically hypertensive
(LH) rats exhibit increased excretion of thromboxane (Tx)B2 associated
with enhanced renal vascular resistance (RVR) and decreased pressure
natriuresis compared to those of the normotensive (LN) and low blood
pressure (LL) controls. The aim of the present work was to study the
contribution of this increased TxA2 synthesis to the functional abnor-
malities observed in response to NE administration. Kidneys were
isolated from 8-week-old male LH, LN and LL rats and perfused with
a cell-free solution in a single pass system. The effects of increasing
concentrations of NE on RVR and on natriuresis were studied before
and after blockade of the TxA2 receptors by AH 23848 (4 x 106 M,
Glaxo, UK). Means (± SCM) of the NE-induced changes of RVR (
RVR, mm Hg/ml/min/g) and of the slope of the pressure-natriuresis
(SPN) were as follows:
LL
(N=6)
LN
(N=6)
LH
(N=6)
Before AH (control)
RVR NE 3.5 X108M 0.64
±0.1
1.12
±0.3
1.27
±0.4
NE 1.1 x107 M 2.77 3.97
±0.6
6.56
±o.9
NE 3.2 X107 M 5.72
±1.1"
9.84
±1.3
14.2
15a,b
SPN 0.05
±0.04
0.04
±0.02
0.001
0,01a.b
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LL(N=6) LN(N=6) LII(N=6)
After AH
A RVR NE 3.5
NE 1.1
NE 3.2
XIO
X107
>(iO'
M
M
M
0.57
2.71
4.63
0.91
3.99
8.65
1.18
4.45
10.15
÷15a,b
SPN 0.09 0.05
0.05 P <0.05 vs. LN rats;" P < 0.05 vs. control
period
Before AH, kidneys of LH rats differed from those of LN and LL by
enhanced RVR and decreased pressure-natriuresis. All did not modify
the NE effects in LL and LN kidneys but significantly reduced the A
RVR and increased the pressure-natriuresis of LII kidneys. In conclu-
sion, the increased ability of LH kidneys to synthesize TxA2 contrib-
utes to their abnormal functional responses to NE.
Adult type I primary hyperoxaluria: Two cases diagnosed by liver
biopsy at end-stage renal failure. F. Schillinger, M. Mahmoud, R.
Montagnac, P. Collin, T. Mi/cent, Services de Nephrologie-Hemodia-
lyse, CHG Troyes et CH Cholet, France. Type I primary hyperoxaluria
is a rare autosomal recessive disease characterized by a deficiency of
alanine-glyoxylate aminotransferase (AGT) activity. Its diagnosis is
based on the demonstration of increased urinary oxalate in children and
young adults, who suffer from recurrent renal stones and nephrocalci-
nosis which rapidly progress to renal failure. However, at end-stage
renal failure, oxaluria is no longer interpretable and the diagnosis
becomes more and more difficult when the disease has been latent for a
long time and is only discovered at a late stage. This is demonstrated in
the two following cases. A 63-year-old woman, without nephrolithiasis
or nephrocalcinosis, presented, after an 18-month dialysis period, with
cutaneous, bone and renal oxalosis. A 66-year-old woman, with an
history of recurrent renal stones and nephrocalcinosis, presented rapid
deterioration of renal failure after renal surgery and developed bone
oxalosis during dialysis treatment. In both observations, AGT activity
was deficient in the liver obtained by percutaneous needle biopsy. It is
necessary, in late-onset disease, to search for extrarenal localizations,
which may, however, occur in oxalosis secondary to renal failure. In
fact, at that stage, diagnosis of primary hyperoxaluria can only be made
by liver biopsy with enzyme activity determination.
Effects of intravenous (i.v.) cyclophosphamide (Cy) in proliferative
lupus glomerulonephritis (GN). M. Delahousse, P. Dosquet, MA.
Artaz, H. Fessi, S. Kenouch, J.Ph. Méry, Department of Nephrology,
Hopital Bichat, D. Nochy, Department of Pathology, Hôpital Brous-
sais, Paris, France. Effects of i.v. Cy in proliferative lupus GN were
retrospectively evaluated in 10 patients (pts) (10 females, mean age 32
yrs) who each received 6 monthly iv. boli of 0.7 g/m2 Cy, together with
degressive doses of prednisolone (TO, 0.75 0.15 mg/kg/day; T6, 0.30
0,03 mg/kg/day). Renal biopsies were performed before the treatment
was started (TO) and one month after the 6th bolus (T6). At TO, 8 pts had
diffuse and 2 focal proliferative GN. Lupus was clinically and immu-
nologically active in all, and 5/10 pts had extrarenal manifestations.
Proteinuria was >1 g/day in 9/10 pts, with nephrotic syndrome in 4.
Renal insufficiency (serum creatinine >120 /LM) was present in 5/10. At
T6, lupus was quiescent in all pts and immunological activity had
disappeared in 8/10. Proteinuria >1 g/day was still present in 5 pts, 3 of
whom were still nephrotic (they all had subepithelial deposits on the
initial biopsy). Renal biopsy showed a regression of active lesions in all
pts (activity index: 4 1 vs. 10 2), however, some degree of
endocapillary proliferation was still present in 7/10. On the contrary,
sclerotic lesions showed a tendency to increase (sclerosis index: 3 1
vs. 2 I). Very few side effects were observed: acute neutropenia
following the 1st bolus in I pt and macroscopic hematuria in another.
Severe flare up (1 renal, 2 neurological) occurred in 3 pts between the
3rd and 4th months following the last bolus. Conclusion: Monthly iv.
bolus of Cy has a favorable effect on renal and extra-renal manifesta-
tions of SLE and allow reductions of steroid doses. Short-term toler-
ance is good. However, this treatment seems unable to prevent the
development of sclerotic lesions. The persistence of endocapillary
proliferation at T6 and the occurrence of flare up shortly after the 6th
bolus suggest pursuing the bolus of Cy beyond the 6th month.
Frequency and significance of monoclonal gammapathies in renal
transplant patients. D. Hestin, F. Bertrand, E. Renoult, M. Kessler,
Service de Nephrologie (Pr. Huriet), Laboratoire de Biochimie (Pr.
Paysant) CHU de Nancy-B rabois 54511, Vandoeuvre les Nancy Cedex,
France. Routine search for a monoclonal immunoglobulin was con-
ducted from 1 April 1986 in 172 functional renal transplant patients, of
which 90 were included in a prospective study. Monoclonal gammapa-
thies (MG) are frequently encountered in renal transplant patients,
affecting 23% of the population (prospective study) versus 1.25% in a
reference population of over 50 years. They appear early after trans-
plantation, the average interval being 7.3 months (extr. 10 days, 14.8
months). The immunologic structure of the secreted monoclonal com-
ponent is similar to that of the monoclonal gammapathy of "undeter-
mined significance". In 69% of cases it is composed of a heavy chain
gamma and in 68% of cases, a light chain kappa. Fourteen percent are
composed of biclonal forms. Only moderate quantities of monoclonal
immunoglobulin are secreted (less than 10 mg/liter). We did not observe
any malignant transformation after a period of 2—26 months. No
significant correlation could be made as far as age (average age of
patients presenting MG being 45 years and 42 years in the population
devoid of MG), duration of initial immunosuppressive treatment, num-
ber of acute rejections and viral infections due to cytomegalovirus and
Epstein-Barr virus. The frequency of monoclonal gammapathy is higher
in patients treated by cyclosporine compared to patients receiving
azathioprine and prednisone (P < 0.024). The patients presenting with
chronic rejection as well as those having chronic hepatitis B infection
are at a high risk of developing a MG (P < 0.003 and P < 0.0001,
respectively). To conclude, the occurrence of a monoclonal gammapa-
thy seems frequent in immunosuppressed renal transplant patients; the
exact initiating immunological mechanism(s) remain to be established.
Consequently, a prospective study is currently being made to determine
the relationship between the secretion of a monoclonal immunoglobulin
and chronic rejection.
Effects of captopril on post-renal transplant erythrocytosis (PTE). M.S.
Islam, B. Bourbigot, J.P. Codet, J. Cledès, University Hospital Mor-
van, 29285 Brest Cedex, France. We observed a coincidental correction
of PTE in two of our hypertensive PTE patients receiving captopril (C).
As C is known to worsen anemia in chronic hemodialyzed patients, we
were encouraged to carry out a prospective study in 7 hypertensive,
cyclosporine A (CsA)-treated kidney recipients suffering from PTE by
treating them with C: mean age: 40 10 years; 6 male: 1 female; onset
of PTE: 6 to 28 months after transplantation (Tx); duration of PTE: 1 to
31 months; duration of study: 1.5 to 6.8 months. All patients manifested
true erythrocytosis [red blood cell (RBC) mass > 20% of predicted
levels] and had stable renal functions. After informed consent, they
were treated by 75mg/day of C. During the study, smoking habits, body
weights and treatments remained unchanged.
RBC
N— 7
RBC
mass
mi/kg
mass
plasma
vol (%)
RBC
count
x]06/mm3
Hct
%
Hb
g/dl
Diastolic
BP
mm Hg
Serum
creat.
p.mol
Before 42 94 6,5 56 18 94 139
C±SD ±4 ±15 ±0.3 ±5 ±1.5 ±7 ±29
After 31 73 5.0 45 15 82 138C + sD±5a a9b ±0.9" ,5a 16b 8b ±20
a p < 0.005, b p < 0.01
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Comments: (1) Captopril induced correction of PTE in all patients. (2)
There was no graft dysfunction or hyperkaliemia. (3) Diastolic blood
pressure (BP) was significantly reduced. Hypothesis: (1) Reduction of
erythropoietin (EPO) production is a result of decreased angiotensin II
which is known to exert a direct effect on EPO production. (Fried W, et
al: J Lab Gun Med 99:520.-.525, 1982). (2) Improvement of renal tissue
ischemia by postglomerular vasodilatation by C. Conclusion: Captopril
may be a simple, safe and nonaggressive treatment of PTE.
Hydropenia potentiates the renal response to an oral protein load. A.
Hadj-AIssa, M. Fraysse, L. Bankir, M. Laville, P. Zech, N. Pozet,
Service d'Exploration Fonctionnelle Rénale and Service de Néphrolo-
gie, Hopital E. Herriot, 69437 Lyon Cédex 03, and INSERM U90,
Hôpital Necker, 75743 Paris Cédex 15, France. In ten healthy volun-
teers, the renal response to an oral protein load (1.5 g/kg) was evaluated
at 2 week intervals, the subjects being placed either in hydropenic
conditions (low hydration = Lo H) or in water diuresis (high hydration
= Hi H). Urinary flow rate (V), free water clearance (CH2O), inulin
clearance (GFR), and fractional reabsorption (FR) of Na and Cl were
measured 1 hour before (TO) and 1, 2, and 3 hours after ingestion of a
protein meal (TI, T2, and T3, respectively).
TO Ti T2 T3
HiH LoH HiH LoH HiH LoH HiH LoH
V mI/mm 13.9 3.1 10.2 2.2 12.2 2.6 12.3 2.5
Crn1/min 9.0 —1.9 5.1 —2.4 6.5 —2.8 5.7 —3.3
The GFR increase was chronologically more homogenous in Lo H than
in Hi H. Conclusions: (1) This comparative protocol shows that the
renal functional reserve induced by the protein load is greater and more
synchronous when the subjects are not placed in water diuresis. (2) The
increase in urinary concentrating activity after the protein load suggests
that urinary concentrating processes contribute either to induce or to
enhance the post-prandial hyperfiltration. (3) That FRNa and FR1
increase in Lo H and decrease in Hi H suggest giomerulo-tubular
imbalance in Lo H. This imbalance could contribute to the higher
solicitation of the renal functional reserve.
Intracranial aneurysm and autosomal.dominant polycystic kidney dis
ease: Preliminary results of a cooperative study. D. Chauveau, I'. Pirson,
J.P. Grunfeld, Département de Néphrologie, Hópital Necker, Paris,
France; Service de Nephrologie, Cliniques Universitaires Saint-Luc,
Bruxelles. In patients with autosomal-dominant polycystic kidney dis-
ease (ADPKD) the rupture of intracranial aneurysm (ICA) is one of the
most life-threatening manifestations. Its incidence is probably low
(about 10%), perhaps with familial aggregation. In February 1990, 500
questionnaires were sent to nephrologists in France, Belgium and
Switzerland. To date, 48 cases (ICA + ADPKD) have been identified.
ICA rupture occurred at a mean age of 39 years (15—65), before the age
of 50 in 80% and affected females and males equally. The most frequent
symptoms were subarachnoid hemorrhage (32/46 patients), neurological
deficit (N = 12), and loss of consciousness (N = I). In one case, ICA
was detected by arteriographic screening. Before the rupture 9/34
patients had normal blood pressure, and 24 were hypertensive ( 160/95
mm Hg). At the time of the rupture renal function was in the normal
range (serum creatinine < 120 molIliter) in 54% patients, moderately
altered in 24%, severely altered in 17% (serum creatinine > 400
jsmol/liter). Two patients were on dialysis. Ruptured ICA (N = 39) were
located on the middle cerebral artery (59%), the anterior communicat-
ing artery (18%) and the anterior cerebral artery (13%). In 14/40 patients
(35%) one or more unruptured ICA were detected. Fourteen patients
were not operated; 4 died promptly (5 months), 10 had prolonged
survival, 6 of them without neurological impairment. Thirty-four pa-
tients had elective surgical repair: 2 died post-operatively, 14 had
severe (N = 9) or moderate (N = 5) disability and 18 are free of
sequellae. Five patients experienced recurrent rupture of another ICA,
6 to 14 years after the initial rupture. In three of these patients the
second aneurysm had not been visible on the first arteriography. In 37
patients, a family history was available: ICA rupture had been proven
in one relative in 3 families and strongly suspected in 7 others. In
conclusion, this study suggests that (1) 80% of ICA rupture in ADPKD
patients occurs before 50 years; (2) 9—27% of these ruptures are
associated with a positive family history of ICA; and (3) the risk of
recurrent rupture may be as high as 20% at 10 years.
Membrane characteristics have an effect on monocyte stimulation in
patients receiving chronic hemodialysis (HD). G. Stamatakis, H. Fessi,
S. Chollet-Martin, S. Bailly, M.A. Gougerot-Pocidalo, J.Ph. Méry,
Department of Nephrology and Department of Immunology and He-
matology, Hopital Bichat, Paris, France. To assess the influence of HD
membrane characteristics on the production of TNFa, plasma concen-
tration of TNFa and both spontaneous and LPS-induced monocyte
capacity to produce TNFa ex-vivo were studied in 33 patients (pts) with
chronic renal failure dialyzed for a mean period of 33.5 months. The
study was done during a 210 mm HD session performed with a dialysate
of high bacteriologic quality, with either a cuprophan (CUP) (N = 21),
a cellulose acetate (CA) (N = 6) or a polysulfone (PS) (N = 6)
membrane after at least one month of use of the same membrane.
Results:
Plasma
T0
TNFaa
T210
Monocyte supernatant TNFa
Spontaneousb
T0 T210 T0
LPSC
T210
CUP
CA
PS
396d
49.0"
40.8"
59.8e
44.5
39.2
612
550
985
6343
1988
1224
2757
2380
3831
l8832
3826
5369
a Controls: <15 pg/mI. b Controls: 227 40 pg/S x lO monocytes.
C Controls: 2574 513 pg/S x l0 monocytes. "P < 0.05 vs. controls.
P < 0.001 vs. T0. ' P < 0.05 vs. T0
Conclusions: (I) Plasma TNFa and monocyte capacity to produce
TNFa are both significantly increased in HD pts whatever the mem-
brane characteristics; (2) Only with CUP membrane is their increase
during the HD session significant. These results suggest that: (1) HD pts
exhibit a state of chronic stimulation of monocytes in terms of TNFa
production; (2) CUP, more than CA and PS, has a stimulatory effect on
the production of TNFa by circulating monocytes.
Prevention of hyperparathyroidism in patients on maintenance dialysis
by intravenous one alpha hydroxy.vitamin D3 in association with Mg
(OH)2 as sole phosphate binder. A randomized comparative study with
the association of CaCO3 Mg(OH)2. C. Maurouard, Ph. Moriniere, B.
Boudailliez, P.F. Westeel, R. Bouillon, R. Pamphile, A. Fournier,
CHRU Amiens, France, Clinique Saint Rafael, Louvain, Belgique,
Laboratoire Leo France, Forty-seven uremic patients on maintenance
dialysis previously stabilized with treatment by oral CaCO3 and if
necessary Mg(OH)2 as phosphate binder while their dialysate had a Ca
at 1.65 and a Mg at 0.2 mmol/liter were randomized into a control group
of 24 who were maintained on the same treatment and a group of 23 who
discontinued CaCO3, received i.v. la(OH)D3 after each dialysis at
increasing doses up to 4 g and increased their dose of Mg(OH)2 given
as sole phosphate binder. The evolution of the relevant parameters is
summarized in the table: P < 0.5 versus TO).
HIM I LthI
FRI1s NiH —*— FRCI HINI FRNaLoH £ FRCI LaN
I
C,
0,8
&e 0,4
0,0
-0,4
-0,8TO TI '12 T3
* p <005 versus BiB
TO TI 12 Ti
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TO
CaCO3
NormaiN = 24
Mon
1 alpha CaCO3N = 23 N = 23
th 2 Mon
1 alpha CaCO3
N = 23 N = 23
th 6
1 alpha
N = 18
Con-. Ca 2.3—2.7 2.55 2.45 2.53 2.69a 2.50 2.49
mmol/
liter
P04 mmol/ 0.8—1.2 1.58 1.57 1.61 2.03a 1.70 1.77a
liter
Mgmmol/ 0.7—0.9 1.1 1.0 1.1 1.2a 1.10 1.2a
liter
K mmol/ 4.5—5,5 5,50 5.20 5.40 5.6 5.50 5,9ØU
liter
Phaic (II! <170 110 112 108 114 121 103
liter
P111 1-84 3—40 75 90 52 43 103 74
pg/mi
DOse Ca 5.8 6.3 6.6 6.6 —
Co3
g/day
Dose I — — — 1.85 — 0.62
alpha
pg/dial-
ysis
Dose 1.1 0,7 1.1 2.1 1.4 2.2
Mg(OH)2
g/day
Since a previous histological study had shown that plasma 1-84 PTH >
70 pg/mI corresponded to severe osteitis fibrosa, we divided our
patients into 2 subgroups according to PTH value. Among those with
initial hyperparathyroidism (HP) 5 out 7 patients treated with CaCO3
and 6 out of 8 treated with 1 a had high PTH. Among those without
initial HP, 3 out of 17 of the CaCO3 group and 2 out of 15 of the la group
had at 6 months a PTH > 70 pg/mI. In the HP group la induced,
however, a significant decrease in PTFI at 2 months but this effect was
transient because the dose of Ia had to be reduced, since the induced
hyperphosphatemia could not be adequately controlled by Mg(OH)2.
The tolerance of this latter at high doses was limited by diarrhea and
hyperkalemia. Conclusion: (I) CaCO3 and i.v. 1 a(OH)D3 are similarly
capable of preventing HP in most dialyzed patients. (2) However, these
2 treatments are unable to correct permanently an established frank
hyperparathyroidism. i.v. la(OH)D3 leads only to transient suppression
of PTH hypersecretion because its doses have to be reduced since the
induced hyperphosphatenila cannot be prevented by tolerable doses of
Mg(OH)2.
Erosive spondyloarthropathy in peritoneal dialysis patients. P. Bindi,
A. Prier, C. Michel, F. Mignon, Service de Nephrologie, Hôpitai
Tenon, and Service de Rhumatoiogie, Hôpital Saint-Antoine, Paris,
France. Erosive spondyloarthropathy (ESA) is a well-known entity in
hemodialyzed patients, but has not yet been reported in patients on
peritoneal dialysis (PD). A retrospective aim of our study was to
evaluate ESA in patients alive on PD in our center and alive at 31
August 1989. Routine annual X-rays of the cervical and lumbar spines
was available in 86/93 patients. ESA was defined by a severe narrowing
of the disk-space with erosive changes of the vertebral plates. ESA was
present in 17 patients (19.7%); none of them had evidence of disk-space
infection. Seven of 17 had secondary hyperparathyroidism; their mean
PD duration was 22.8 + 17.5 months (0.5—62). None had been previ-
ously treated by hemodialysis. The lower cervical spine was involved in
all cases. In addition ESA was encountered in the CIC2 level in one
patient, and in the dorsal spine in another. Pain and stiffness were
usually moderate. Patients with ESA were older (75.8 + 9 years) than
those without ESA (6.87 + 11.8 years; P < 0.01). There was no
difference in the 2 groups regarding causal nephropathies, duration of
PD, serum levels of calcium, phosphorus, PTH, alkaline phosphatases
and aluminum, presence of osteoarthritis of the spine and/or ectopic
calcifications. This study demonstrates that ESA is also common in PD
patients. In some cases, PD duration was quite short. Old age and
erOsive changes induced by hyperparathyroidism or previous degener-
ative lesions probably play a major in the pathogenesis of ESA.
Renal handling of a1-microglobulin in uninephrectomized rats. C.
Bianchi, C. Donadio, G. Tramonti, C. Vannucci, V. Ricchiuti, A.
Casani, P. Giannotti, M. Cecchi, C. Bonino, E. Seccamani, F. Lunghi,
Unitd di Nefrologia, Clinica Medica 2, UniversitO di Pisa; Clinica
Uroiogica 2, Universitá di Pisa; SORIN Biomedica, Saluggia VC,
Itaiia. In normal animals many low molecular wt proteins, such as
a1-microglobulin (a1m), are highly accumulated by the kidney and their
urinary excretion is generally low. To verify whether the reduction in
renal mass can modify this behavior, kidney uptake and urinary
excretion of human labelled a1m have been determined in uninephrec-
tomized rats (UNI). The experiments were carried out in 32 Sprague-
Dawley male rats (260—400 g). Sixteen animals underwent right ne-
phrectomy. Two weeks after surgery, UNI and an equal number of
control rats (C) were injected with a1m labelled with 1-13 1. Nine UNI
and 9 C were sacrificed at the 18th mm after injection of radioiodinated
a1m (time of maximum kidney uptake of a1m in normal rats). Seven
UNI and 7 C were sacrificed 10 mm later, at the 29th mm. The results
(percent of injected dose, mean s; 'P < 0.05, bp< 0.001) are shown
in the Table.
Radioactivity
18th mm 28th mm
UN1 C UNI C
of:
Plasma (1 g) 2.74 0,20b 2.05 0.22 1.84 016b 1.41 0.05
Left kidney 29.52 3,40b 19.92 2.33 27.96 2,18b 17.35 2.07
(tot)
Left kidney 19.87 2.54 17.55 2.39 17.57 1.78a 15.00 1.99
(1 g)
Urine (total) 6.13 2.56" 3.98 1.37 7.03 2,41 5.85 1.98
Conclusions: In UNI plasma retention, kidney accumulation and uri-
nary excretion of a1m are higher than in C. The increase in kidney
accumulation of a1m after unilateral nephrectomy (and of other low
molecular wt proteins with the same behavior) could play a role in the
progression of kidney injury in this condition.
Protein C (PC) deficiency and renal transplantation: Efficacy of re-
placement therapy by purified human PC. 0. Toupance, Ph. N'Guyen,
J.J. Dion, A. Wynckei, S. Lavaud, J.P. Melin, J. Chanard, Service de
Nephrologie et Laboratoire d'Hematologie, Centre Hospitalier ci
Universitaire, Reims, France. PC is a vitamin K dependent protein with
an inhibitory effect on coagulation and a stimulatory effect on fibrino-
lysis. PC deficiencies are associated with increased risk of thrombosis,
We report the first case of successful renal transplantation performed
using large doses of purified human PC in a patient with interstitial
nephritis and congenital PC deficiency type II. Familial PC deficiency
was diagnosed after the patient was explored for severe thrombotic
events (thrombosis of all vascular accesses, mesenteric infarction).
CAPD was thus the only adequate solution to treat end-stage renal
failure. Human PC was purified from a pool of blood donors (Dr.
Burnouf, CRTS Lille). Tolerance and kinetics were tested in the patient
prior to transplantation: 24 hrs after administration of 50 lU/kg, antigen
level was 135% and amidolytic activity was 99%. A cadaver renal
transplantation was performed with sequential immunosuppression
(antilymphocyte globulins, steroids, azathioprine and cyclosporin A).
Hypocoagulation and sustained normal PC activity were obtained using
standard heparin and purified PC, respectively. PC was administered 3
hrs prior to surgery and continued for 18 days, at the dosage of 100
lU/kg/day for 10 days, then at 50 lU/kg/day. The patient was discharged
on low molecular weight heparin. At day 45, a rejection episode was
successfully treated while the patient received purified PC, At 3 months
post-transplantation, the patient had normal renal function and was free
of thromboembolic complications. This case indicates that replacement
therapy with PC allowed successful renal transplantation in a patient
with a severe thromboembolic disease due to congenital deficiency in
PC. Such efficient therapy can therefore be suggested to overcome the
risks of post-surgical thromboembolic complications, particularly in
hepatic transplantation, in patients with congenital or acquired PC
deficiencies.
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Oftoxacin in renal transplant patients with legionellosis: Absence of
metabolic interference with cyclosporin A. A. Wynckel, 0. Toupance,
J.P. Melin, C. David, S. Lavaud, T. Wong, J. Chanard, Service de
Nephrologie et Laboratoire de Bacteriologic, CHRU Reims, France.
The high mortality rate of severe pneumonia due to legionella infection
in immunocompromized hosts requires quick and efficient therapy.
Patients with impaired immune defenses have been reported not to
respond to erythromycin. In such cases, the association of erythromy-
cm with Rifampicin has been proved to be successful. However, in
transplant recipients, these antibiotics interfere with cyclosporin A
metabolism. A good efficiency of new fluoroquinolones has been
recently described in experimental legionellosis. In man, their beneficial
effect is not well documented, particularly in transplant patients receiv-
ing cyclosporin A. Among 12 bacterial pneumonia observed in 81 recent
renal transplant recipients, seven were due to legionella infection. For
the six patients having a functional graft, pneumonia occurred after an
average 17 days following the transplant rejection treatment. Diagnosis
was made using bronchoalveolar lavage: direct immunofluorescence
antigen technique was positive in five patients and culture in six
patients. Legionella pneumophila serogroup 5 and 1 were identified in
one and five patients, respectively. Six of these patients were treated
with ofloxacin. The fluoroquinolone was efficient in all cases. It was
administered as single therapy in three patients and did not modify
blood cyclosporin A concentration. Ofloxacin given at the dose of 400
mg per day and adjusted to renal function is an effective and well
tolerated treatment of legionellosis in transplant recipients receiving
cyclosporin A.
Lupus glomerular nephritis and silica exposure. Th. Bensousan, R.
Tanneau, J.P. Leroy, J. Cledes, Department of Nephrology, Depart-
ment of Pathology, University Hospital of Brest, France. The combi-
nation of silicosis and collagenosis is classical (Kaplan-Collinet, Eras-
mus syndrome). However, lupus occurring in the course of silicosis is
uncommon in spite of the frequent positivity of antinuclear antibodies in
silicosis (34 to 45%). We report here 2 cases of proliferative glomeru-
lonephritis in lupus with silica exposure. Case 1: A 59-year-old male
sand-worker developed systemic lupus erythematosus (SLE) in the
course of histologically proven silicosis. SLE was associated with
segmental glomerulonephritis characterized by lgG, IgA and C19
deposits. End-stage renal failure occurred over a 2 year period. Case 2:
A 61-year-old male patient with a 15 year history of silica exposure
without silicosis developed segmental glomerulonephritis. Antinuclear
antibodies were present at 1/1000; anti-DNA antibodies were negative.
Hypocomplementemia was demonstrated (CH5O = 41). Between the 2
extreme situations represented by SLE occurring in the course of
silicosis and polyclonal activation with antinuclear antibodies and no
clinical manifestation, an uncommon intermediate pattern in which
toxic exposure is associated with glomerulopathy, antinuclear antibod-
ies with clinical expression of variable intensity may be observed.
Evaluation of intracellular and extracellular volume before the hemo-
dialysis session: Its use for determination of hemodialysis strategy and
interdialytic sodium intake. J.F. Subra, P. Tirot, P. Bucher, G. Balit, M.
Dhib, F. Cogny van Weydevelt, P. Ribéri, Service de Nephrologie,
CHRU d'Angers, 49033 Angers Cédex, France. Hypertonic dialysate is
often used to improve the hemodynamic tolerance of dialysis sessions.
To evaluate this, we studied 46 patients treated in our unit. Whole body
water, intra— and extracellular volume were determined before the first
session of the week for two successive weeks. These data were
evaluated using a model developed from Murisasco, Kimura, and
Gotch's studies. During the hemodialysis session, we reported all
"symptomatic" hypotension, that is, clinical manifestations necessitat-
ing vascular filling. Results:
Nber age
weight
gain
% /
poids
7
intra-C
7
extra-C
Session 1 46 59 1.7 Kg 3.4% 1.5% 12%
Session 2 46 59 2 Kg 3.4% 1.4% 13%
Two episodes of hypotension were reported the first week and only one
the second week. Elevation of intracellular volume was respectively
1.8%, 7%, and 0.4%. There was no difference between results obtained
in patients treated with acetate (19 pts.) or bicarbonate buffer (24 pts.),
nor with patients on hemofiltration (3 pts.). Patients necessitating drug
therapy for hypertension (13 pts) had similar results as the others. In
our population, weight gain between two dialysis session is mainly
related to extracellular volume filling. We think this is due to the liberal
sodium diet (120 mmol!day) given to our patients. The good hemody-
namic tolerance of dialysis session is related to the low weight variation
(3.4% the first day of the week) and the low elevation of intracellular
volume. Liberal sodium diet is not associated with hypertension; only
30% of our patients require antihypertensive drug therapy. Sodium
concentration used in the dialysate is 140 mmollliter. Sodium concen-
tration variation and ultrafiltration rate can be monitored during the
session. However, the value of these data must be discussed according
to the validity of the model used.
Hemodynamic changes and vasopressive hormones in hemodialyzed
patients treated with erythropoietin (rHuEPO). J.M. Poux, J.P.
Charmes, Ph. Lacroix, G. Lachatre, F.X. Galen, G. Nicot, C. Leroux-
Robert, Service de Nephrologie, CHU Dupuytren, F 87042 Limoges,
France. The mechanisms responsible for hypertension in hemodialyzed
patients (HDP) treated with rHuEPO are not well defined. To evaluate
the effect of rHuEPO on changes in hemodynamics and cardiac
morphology (echocardiographic evaluation) as well as vasopressor
hormones, 10 HDP treated with rHuEPO were studied. MAP and DAP
rose significantly only towards the end of HD. Systemic vascular
resistance (SVR) did not significantly increase. Cardiac output, pulse
rate, stroke volume and cardiac morphology indexes were not modified.
H-ANP 1-28 significantly decreased with HD before (140 8 to 67 4
pg ml; P <0.01) or after rHuEPO (123 8 to 67 3 pg ml'; P <
0.01); H-ANP 1-28 was not changed by rHuEPO. Plasma concentra-
tions of free and total norepinephrine (NE) and epinephrine, and of total
dopamine increased with rHuEPO before and after HD. Only free NE
significantly increased after HD(183. 4 27.6 to 272.4 31.8pg
P < 0.05). The MAP and SVR increase was not correlated with the
increase in hematocrit. Hypertension appeared in 3 HDP with high
cardiac output before rHuEPO. Their cardiac output inadequately
decreased compared with the increase in SVR. We conclude that
rHuEPO increases free NE and blood pressure at the end of dialysis.
Other parameters remain unchanged. It is possible that hypertension
appears in some patients with inadaptability of cardiac output to a slight
increase in SVR.
Improvement of survival and renal function in stage III B myeloma
using VAD or VAD-PECC chemotherapy. P. Tirot, A. Goldstein, M.
Dhib, F. Babinet, F. Cogny van-Weydevelt, E. Kernaonet, P. Lebon,
J.F. Subra, Service de Nephrologie CHRU Angers, Service de Néph-
rologie CHG Le Mans, France. VAD = (vincristine-adriamycin-
dexaméthasone)/PECC = (prednisone-eldisine-carmustine-cyclophos-
phamide). Management of high tumoral mass multiple myeloma (MM)
is often done in nephrological units because of renal impairment. We
report a retrospective study of MM therapy using induction chemother-
apy with VAD or VAD-PECC in two different clinical units from 1986
to 1989. Our data concern 16 patients presenting stage III B myeloma
with advanced renal failure (creatininemia = 607 imolIliter 287)
when beginning the treatment.
Median age
(years) IgG IgA
Light chain
myeloma
65.7 7.9 4 kappa-3 lambda 3 lambda 2 kappa-4 lambda
Response
ratea
Renal
function'
Response
time
Median
survival
13/16 13/16 2.8 l.3rno 20 mo (at 1/3/90)
a Therapy response = 50% decrease in seric monoclonal component
b Renal function improvement = 50% decrease in creatininemia
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Chemotherapy using high-dose dexamethasone, vincristine and adri-
amycin infusion was shown to have rapid efficacy on tumor mass
(Barlogie et a!., 1984). Moreover, absence of interaction between these
drugs and renal function led us to use this therapy regimen in our
patients: (1) deaths: 12 patients died, 7 from myeloma, 3 from infection.
(2) median duration of survival in stage III B myeloma is usually
reported to be about 12—14 months. Our results seem better, leading us
to use VAD as remission induction therapy. Maintenance treatment is
discussed: therapy with interferon, other drug combinations and even-
tual bone marrow transplantation.
CNS-induced hyponatremia in the elderly. SIADH or salt wasting
syndrome? R. Tanneau, J.F. Maria, J.P. Code!, J.M. Boles, J. Cledes,
Y. Pennec, G. Le Menn, Service de Nephrologie, CHU BREST,
France, Inappropriate antidiuresis is a well recognized feature in CNS
diseases. Hyponatremia (125 5 mmol/liter) developed in four elderly
patients after head injury (N = 2), during multifocal brain ischemia of
recent onset (N = 1) or unexplained confusion unrelated to hypona-
tremia (N = 1). CT scan disclosed marked cerebral atrophy in all of
them. Increased urinary sodium excretion with high Uom and plasma
AVP levels (1.8 1.3 pmollliter) were consistent with SIADH. How-
ever, ECF loss was demonstrated with impaired skin turgor, changes in
body weight and hematocrit, and high renin activity (PRA); thus, it
could have induced nonosmotic AVP secretion. Moreover, high urine
sodium and high urinary output persisted after sodium and water
restriction. Sodium loss and neurological disturbances were transient in
one case but persisted in the three other patients, resulting in death in
two cases, although in one of them, transient neurological improvement
induced a fall in sodium excretion with positive sodium balance.
Although basal (97 8 pg/mI: N = 12—125) and stimulated plasma
aldosterone concentrations were rather low, regarding PRA (3.26
1.15 ng/mL/hr; N 0.15—2.33), in the absence of glucocorticoid defi-
ciency or heparin therapy, this was not a likely explanation for massive
renal sodium loss. Renal function was normal, without metabolic
acidosis or other evidence of tubular dysfunction. Thus, another
mechanism, for example, inappropriate secretion of a natriuretic factor
which could be related to the CNS involvement, is worth discussing.
Whatever this mechanism is, these patients should not be treated with
water restriction and they could benefit from fiudrocortisone acetate
administration.
